• Explore /
  • Poster
  • / Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM].

Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM].

Abstract Video & Slides Poster

Authors

Aaron Gerds

Aaron Thomas Gerds

Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH

Aaron Thomas Gerds , Srdan Verstovsek , Alessandro Vannucchi , Haifa Kathrin Al-Ali , David Lavie , Andrew T. Kuykendall , Sebastian Grosicki , Alessandra Iurlo , Yeow Tee Goh , Mihaela Cornelia Lazaroiu , Miklos Egyed , Maria Laura Fox , Donal P. McLornan , Andrew Perkins , Sung-Soo Yoon , Vikas Gupta , Jean-Jacques Kiladjian , Rafe Donahue , Jun Kawashima , Ruben A. Mesa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT04173494

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7061)

DOI

10.1200/JCO.2022.40.16_suppl.7061

Abstract #

7061

Poster Bd #

292

Abstract Disclosures

Similar Posters

First Author: Lucia Masarova

First Author: Yi Zhang

First Author: Yi Zhang

First Author: Vikas Gupta